With the explosion of interest in cancer immunotherapy and the proliferation of scientific meetings in the field, the time is right for a coordinated effort hosted by the field's leaders. The Cancer Research Institute (CRI), the Association for Cancer lmmunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) are proud to join forces once again to sponsor the Second International Cancer lmmunotherapy Conference.

The 2016 meeting will take place at the Sheraton Times Square Hotel and the New York Hilton Midtown in New York City from September 25-28, 2016. The program will focus on "Translating Science into Survival," and feature talks from more than 60 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy, including: antigens and vaccines, emerging technologies, mechanistic merging of treatment modalities, microbiota, new agents and their mode of action, new checkpoints, non-checkpoint immunotherapies, and the tumor microenvironment.

This meeting will provide an unparalleled opportunity for teaching, learning, and networking among all stakeholders in the field: scientists, clinicians, regulators, drug developers, and patient advocates.


Educational portions of Translating Science into Survival are designated as Continuing Medical Education (CME) activities. Commercial entities that support these activities are required to comply with the Standards of Commercial Support of the Accreditation Council for Continuing Medical Education (ACCME).